Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Brad Prather

Orthopaedic Surgery Danville, IN Medical Doctor

NPI 1952445710 CMS profile 43562

100 Hospital Ln, Suite 300, Danville, IN 46122

Open in the dashboard

General payments

$5,703

51 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Brad Prather of Danville, IN is reported in the CMS Open Payments database as having received $5,703 across 51 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 59th percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,347 19
2024 General $2,115 15
2023 General $23 1
2021 General $889 7
2020 General $54 3
2019 General $274 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Brad Prather
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Brad Prather were reported at $2,347. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Brad Prather Orthopaedic Surgery median Middle half National median
2019 $274 $644 $140–$2,844 $163
2020 $54 $312 $75–$1,860 $114
2021 $889 $520 $117–$2,495 $132
2022 $0 $598 $128–$2,731 $149
2023 $23 $461 $128–$2,264 $160
2024 $2,115 $497 $134–$2,475 $164
2025 $2,347 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Smith+Nephew, Inc. $5,272 33 payments
  2. Medtronic USA, Inc. $162 4 payments
  3. Ferring Pharmaceuticals Inc. $120 7 payments
  4. Vertex Pharmaceuticals Incorporated $55 2 payments
  5. Djo, LLC $42 2 payments
  6. DePuy Synthes Sales Inc. $21 1 payment
  7. Zimmer Biomet Holdings, Inc. $16 1 payment
  8. Cumberland Pharmaceuticals, Inc. $15 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $3,718 13 payments
  2. Food and Beverage $1,985 38 payments
Products named General payments · program years 2019–2025
  1. JOURNEY $2,579 10 payments
  2. JOURNEY II Recon Knees $2,472 11 payments
  3. RI Hip Navigation $2,429 9 payments
  4. REAL INTELLIGENCE $1,657 12 payments
  5. LEGION Revision $1,273 7 payments
  6. OR3O Dual Mobility $1,230 5 payments
  7. CORI $889 7 payments
  8. LEGION TKS $734 5 payments
  9. POLARSTEM $626 3 payments
  10. JOURNEY II Recon Knees $525 3 payments
  11. Other $2,691 36 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

283

Median for Orthopedic Surgery: 203

Drug cost

$1,763

Median for Orthopedic Surgery: $1,433

Branded share of claims

8.1%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Celecoxib Generic 17 $461
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 23 $302
Oxycodone Hcl Generic 40 $281
Tramadol Hcl Generic 53 $251
Diclofenac Sodium Generic 12 $213
Meloxicam Generic 68 $158
Amoxicillin Generic 59 $71
Clindamycin Hcl Generic 11 $26

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 76 billing codes

Paid by Medicare

$302,591

Of which drugs: $43,335

Medicare patients

542

Average age 74

Services billed

2,651

346 women, 196 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 29%
Diabetes 27%
Depression 25%
Chronic kidney disease 20%
Atrial fibrillation 16%
Osteoporosis 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, euflexxa, for intra-articular injection, per dose J7323 Office 78 469 $43,188
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 16 136 $93

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

51 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record